Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Kathleen Dungan MD, MPH
Kathleen M. Dungan MD, MPH Advisory Board
Richard Pratley MD
Richard E. Pratley MD Associate Editor
Deborah Wexler MD, MSc
Deborah J. Wexler MD, MSc Associate Editor
See All Experts
featured
Published in Diabetes

Expert Opinion / Commentary · December 19, 2016

2016 Top Stories in Diabetes: A Resurgence of Interest in Pioglitazone?

Richard Pratley MD

 

 Save  Recommend
 Share

Additional Info

  1. Nissen S, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death From Cardiovascular Causes. N Engl J Med. 2007;356(24):2457-2471.
  2. Cusi K, Orsak B, Bril F, et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016;165(5):305-315.
  3. Kernan WC, Viscoli CM, Furie KL, et al. Pioglitazone After Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016;374(14):1321-1331.

Disclosure statements are available on the authors' profiles:

Richard Pratley MD

Further Reading

Most Read This Week

Recently Updated